Biotechnology

Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States

June 15, 2021 10:00 PM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares ('ADSs') at a public offering price of $21.25 per ADS, for total gross proceeds of approximately $63.8 million. All...

Read more

Aqualung Therapeutics Plans A Phase 0 ARDS Trial for eNAMPT Monoclonal Antibody (Alt-100 mAb) Following Type B FDA Meeting

June 15, 2021 3:00 PM

Phase 0 trial in ARDS subjects estimated completion by end of 1st QTR 2022 FDA indicates general agreement on required IND-enabling program for ALT-100 mAb in ARDS patients ALT-100 humanized mAb manufacturing initiated and speeding toward GMP completion TUCSON, AZ / ACCESSWIRE / June 15, 2021 / Aqualung Therapeutics Corp., a biotech company focused on the development of novel therapies to combat unchecked systemic inflammation, completed a...

Read more

Viewpoint Molecular Targeting(TM) Chief Scientific Officer, Dr. Michael Schultz, Discusses the Promise of Image-Guided 212Pb Alpha-Particle Radiopharmaceutical Therapies for Cancer at the SNMMI 2021 Annual Meeting

June 15, 2021 8:30 AM

Presented data highlights the performance of Viewpoint's chelation technology CORALVILLE, IA / ACCESSWIRE / June 15, 2021 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced that Michael K. Schultz PhD, Chief Science Officer of Viewpoint presented at The Society of...

Read more

Oncology Pharma, Inc. Eyes Collaboration with Patent Opportunities Amongst Its Licensed Intellectual Properties

June 15, 2021 8:00 AM

SAN FRANCOSCO, CA / ACCESSWIRE / June 15, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the 'Company') has been continuing its research and work reviewing and implementing collaboration between its interests in therapy, delivery and trial experience amongst its licensed products. The Company is in the early stages of reviewing the work and exploring opportunities between the synergistic value of its licensed Intellectual...

Read more

Marble Arch Research Publishes Analyst Research Report on Nascent Biotech

June 15, 2021 8:00 AM

VERO BEACH, FL / ACCESSWIRE / June 15, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to highlight the publication of an in-depth analyst research report on Nascent Biotech by equity research firm, Marble Arch Research, Inc, which rated NBIO...

Read more

Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs

June 15, 2021 7:05 AM

DehydraTECH™ improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2 KELOWNA, BC / ACCESSWIRE / June 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce positive results from its tolerability and pharmacokinetic ("PK") animal study VIRAL-A20-2, evaluating DehydraTECH-enabled...

Read more

Mosaic ImmunoEngineering Inc. Elects Biotechnology Industry Veteran Robert A. Baffi, Ph.D. to Its Board of Directors

June 15, 2021 7:00 AM

Experience in the Development of Biotechnology and Viral Based Therapeutics Will Help Enhance the Development of the Company's Pipeline NOVATO, CA / ACCESSWIRE / June 15, 2021 / Mosaic ImmunoEngineering Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases, today announced the...

Read more

RepliCel Adds Independent Director

June 15, 2021 6:00 AM

Board of Directors Strengthens Its Independence Oversight and Updates its Stock Options  VANCOUVER, BC / ACCESSWIRE / June 15, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2), (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has appointed Gary Boddington to the board of directors. Gary Boddington is currently the CEO of PlayWize...

Read more

Helix BioPharma Corp. Announces Fiscal Third Quarter 2021 Results

June 14, 2021 6:00 PM

RICHMOND HILL, ON / ACCESSWIRE / June 14, 2021 / Helix BioPharma Corp. (TSX:HBP), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the fiscal third quarter ended April 30, 2021. OVERVIEW The Company reported a net loss and total comprehensive loss of $2,554,000 and $5,268,000 for the three and nine-month periods ended April 30, 2021. For the three and...

Read more

BillionToOne Closes $55M Series B Funding, Builds Out a 36,000 Sqft Space to Meet Growing Demand

June 14, 2021 12:00 PM

MENLO PARK, CA / ACCESSWIRE / June 14, 2021 / Today, BillionToOne, Inc., the precision diagnostics company with the mission to make molecular diagnostics more accurate, efficient, and accessible for all, announced the closure of a heavily oversubscribed Series B funding round of $55 million with premier global investors. Existing investor Hummingbird Ventures and incoming investor Four Rivers Group led the investment round alongside significant...

Read more

EV Biologics is now Pink Current

June 14, 2021 9:00 AM

CHEYENNE, WY / ACCESSWIRE / June 14, 2021 / EV Biologics Corp (OTC PINK:YECO) today announced that it has completed all its filings on OTC Markets and is now Pink Current. Being current and Penny Stock Exempt allows the majority of brokers to trade in our stock. CEO Daniel Mckinney, said 'we are pleased to be current in our filings and are now focused on developing innovative regenerative biologics including engineered exosomes and other stem...

Read more

MERIT Study Investigators Announce Successful Achievement of the Study's Primary Efficacy & Safety Endpoints

June 14, 2021 7:30 AM

AUSTIN, TX / ACCESSWIRE / June 14, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced that investigators of the Multi-Center ESG Randomized Interventional (MERIT) study have reported based on a preliminary analysis the successful achievement of the study's primary endpoints. In a presentation at the 2021 Surgical Disruptive...

Read more

Enzolytics Announces Its Progress Toward Completion of Clinical Trials for Its Anti-HIV ITV-1 Therapeutic and Plans for Its Distribution Throughout Europe

June 14, 2021 7:00 AM

COLLEGE STATION, TX / ACCESSWIRE / June 14, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (http://enzolytics.com/) has concluded definitive plans to advance its previously tested ITV-1 anti-HIV therapeutic to clinical trials and distribution throughout Europe. Completion of these steps will establish its anti-HIV therapy as a significant revenue source for the Company, a meaningful milestone for both human health and Company profitability. The...

Read more

Molecular Partners Announces First Patient Dosed in COVID-19 NIH-Sponsored ACTIV-3 Trial Evaluating Antiviral Candidate Ensovibep

June 13, 2021 4:00 PM

Global Phase 3 trial designed to investigate safety and efficacy of ensovibep in hospitalized adults with COVID-19 Ensovibep receives U.S. FDA Fast Track Designation for the treatment of COVID-19 in both hospitalized and ambulatory settings ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 13, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin®...

Read more

Viewpoint Molecular Targetin(TM) Commences Patient Enrollment in Phase 1 Imaging Study for VMT01 Program for Metastatic Melanoma

June 10, 2021 10:00 AM

- VMT01 Phase 1 imaging study followed by Phase 1/2a therapy study for the treatment of metastatic melanoma being conducted at Mayo Clinic - - Positive preclinical data have demonstrated that a single dose of [212Pb]-VMT01 has significantly arrested melanoma tumor growth and extended survival - - VMT01 imaging study provisional results expected in Q4 2021 - CORALVILLE, IA / ACCESSWIRE / June 10, 2021 / Viewpoint Molecular Targeting, Inc....

Read more

Green Planet Group Secures Long-Term Funding

June 9, 2021 9:00 AM

PHOENIX, AZ / ACCESSWIRE / June 9, 2021 / Green Planet Group, Inc. (OTC PINK:GNPG), an emerging leader in green technology, announced today that it has secured funding that will provide it with the capital required to continue its growth into a profitable company. The investors have already met their initial funding commitments and have pledged additional capital, as needed in the future. According to the investors, "Rarely does an industry...

Read more

Oncology Pharma and Ribera Solutions Release White Paper Regarding Patient Engagement and Retention Platform

June 9, 2021 8:00 AM

SAN FRANCISCO, CA / ACCESSWIRE / June 9, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the 'Company') is releasing a White Paper outlining 5 innovative ways to improve patient engagement in clinical trials. The five key points in the White Paper (which can be found here: https://www.oncology-pharma.com/white-papers are: Health Literacy, Patient Concierge Service, Trial Support Community, Easy-to-use User Interface, and...

Read more

Molecular Partners Announces Launch of American Depositary Shares (ADS) Offering in the United States

June 9, 2021 7:45 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 9, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that it has commenced an initial public offering in the United States of 3,000,000 American Depositary Shares ('ADSs') pursuant to a registration statement on Form F-1 (File No. 333-255447), as amended, that has been filed...

Read more

Pressure BioSciences to Present at the LD Micro Virtual Invitational Conference XI

June 8, 2021 10:15 AM

Company Invites Individual and Institutional Investors, as well as Advisors and Analysts, to Attend the Company's Virtual Presentation on Thursday, June 10, 2021 SOUTH EASTON, MA / ACCESSWIRE / June 8, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform solutions to the worldwide life sciences, agriculture, food &...

Read more

Edesa Biotech to Attend BIO Digital 2021

June 8, 2021 8:00 AM

TORONTO, ON / ACCESSWIRE / June 8, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the company's senior management are scheduled to attend the 2021 BIO Digital Conference being held June 14-18, 2021. Members of the biopharma or investment community who are interested in meeting with Edesa during the conference may contact the company on...

Read more